$0.17
-0.03(-14.55%)
Mkt Cap $17M
$0.17
$0.92
52-Week Range
At a Glance
AI-generatedCost discipline narrowed operating and net losses while improving cash flows from operations despite revenue growth from $1.2M to $1.7M, reflecting tighter controls on personnel and R&D expenses.
8-K
VolitionRx Limited stockholders approved two key proposals at a special meeting on March 31, 2026, authorizing a significant share issuance and a potential reverse stock split.$17M
Market Cap
—
Revenue
—
Net Income
Employees85
Fundamentals
How The Business Makes Money
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Industry Medical - Diagnostics & Research
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000093314
ISINUS9286611077
CUSIP928661107
Phone646 650 1351
Address13215 Bee Cave Parkway, Henderson, TX, 78738, US
SEC EDGAR